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Background: A significant proportion of hemodialysis patients have functional, but modifiable, vitamin K deficiency.
Objective: To determine the correlates of poor vitamin K status in hemodialysis patients.
Design: Cross-sectional study.
Setting: Hemodialysis units at Kingston General Hospital and its satellite centres, Ontario, Canada.
Patients: Patients undergoing outpatient hemodialysis for end-stage kidney disease.
Measurements: Serum concentrations of phylloquinone, undercarboxylated prothrombin, also known as protein
induced by vitamin K absence or antagonism – factor II (PIVKA-II), and the percentage of undercarboxylated
osteocalcin (%ucOC).
Methods: Vitamin K status was determined in fasting blood samples of hemodialysis patients. Bivariate relationships
were examined using parametric and non-parametric statistics as appropriate. Multivariable linear regression models
were applied to identify predictors of vitamin K status.
Results: Among 44 HD patients, criteria for subclinical vitamin K deficiency were met in 13.6% (phylloquinone <
0.4 nmol/L), 51% (%ucOC > 20%) and 90.9% (PIVKA-II > 2.0 nmol/L) of subjects. Phylloquinone levels were positively
associated with total cholesterol, triglyceride levels and non-smoking status. Higher %ucOC was associated with
increased calcium-phosphate product. Increased PIVKA-II levels were observed with advancing age, reduced dialysis
adequacy, lower HDL and a history of coronary artery disease. There were no associations found among the
individual biomarkers of vitamin K status. In a multi-variable model, triglycerides were the only significant predictor
of phylloquinone levels, while increasing phosphate and decreasing PTH were independent predictors of %ucOC.
PIVKA-II levels increased by 0.54 nmol/L for every 10-year increase in age.
Limitations: Observational study; small sample size.
Conclusions: A significant proportion of HD patients met criteria for subclinical vitamin K deficiency. Of the
biomarkers measured, PIVKA-II may be superior given its independence of renal function or dyslipidemia, both of
which may confound the other vitamin K biomarkers. Studies in patients with ESKD linking biomarkers of vitamin K
status to important patient outcomes, including cardiovascular disease, nutritional status and mortality, are required
in order to determine the optimal biomarker for evaluating vitamin K status in this particular population.
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Contexte: Une proportion considérable de patients traités en hémodialyse ont une carence fonctionnelle, bien que
modifiable, en vitamine K. L’objectif de cette étude est de déterminer la corrélation entre une carence en vitamine
K chez les patients en hémodialyse.
Méthodes: Dans le cadre de cette étude d’observation, le statut de la vitamine K était déterminé dans les
échantillons sanguins pris à jeun chez 44 patients en hémodialyse, en mesurant les concentrations de
phylloquinone, de prothrombine non décarboxylée, aussi connue comme la protéine induite en l’absence de
vitamine K ou par antagonisme du facteur II (PIVKA-II), et le pourcentage d’ostéocalcine non décarboxylée (%ucOC).
Les relations bivariées ont été examinées à l’aide de statistiques paramétriques et non paramétriques. Des modèles
multivariés à régression linéaire ont été appliqués pour déterminer les prédicteurs du statut de la vitamine K.
Résultats: Les critères de carence infraclinique en vitamine K étaient remplis chez 13,6% (phylloquinone <
0,4 nmol/l), 51% (%ucOC > 20%) et 90,9% (PIVKA-II > 2,0 nmol/l) des sujets. Les taux de phylloquinone ont été
positivement associés avec les taux de cholestérol total, et de triglycérides, ainsi que le statut de non-fumeur. Un
taux élevé de %ucOC a été associé avec une augmentation du produit phosphocalcique. Des taux croissants de
PIVKA-II ont été observés avec l’âge, le caractère non adéquat de la dialyse, un faible taux de HDL et des
antécédents de coronaropathie. Aucune association n’a été établie parmi les biomarqueurs individuels du statut de
la vitamine K. Dans un modèle multivariable, les triglycérides constituaient le seul prédicteur important des taux de
phylloquinone, alors qu’un taux croissant de phosphate et un taux décroissant de PTH étaient des prédicteurs
indépendants de %ucOC. Les taux de PIVKA-II ont augmenté de 0,54 nmol/l par tranche d’âge de 10 ans.
Conclusions: Une proportion considérable de patients en hémodialyse ont rempli les critères de carence infraclinique
en vitamine K. Parmi les biomarqueurs mesurés, PIVKA-II serait le plus fiable, considérant son indépendance par rapport
à la fonction rénale ou la dyslipidémie, lesquels peuvent confondre les autres biomarqueurs de la vitamine K.
Des études auprès de patients souffrant d’insuffisance rénale terminale permettraient de créer des liens entre les
biomarqueurs du statut de la vitamine K et des résultats importants pour le patient, tels que les maladies
cardiovasculaires, l’état nutritionnel et le décès, et seraient donc nécessaires afin de déterminer le biomarqueur
optimal pour évaluer le statut de la vitamine K dans cette population en particulier.What we know
A significant proportion of hemodialysis patients have
functional, but modifiable, vitamin K deficiency.
What this study adds
Many dialysis patients have sub-clinical vitamin K defi-
ciency and multiple biomarkers can be used to measure
vitamin K status in end-stage kidney disease patients. Pro-
tein induced by vitamin K absence or antagonism - factor
II (PIVKA-II) as a biomarker of vitamin K status has the
advantage of being independent of kidney function and
lipid profile.
Background
Cardiovascular disease is the leading cause of death in
patients with end-stage kidney disease (ESKD), account-
ing for approximately 50% of the annual mortality rate
of this population [1]. In addition to traditional cardio-
vascular risk factors such as hypertension, diabetes mel-
litus and cigarette smoking, kidney-specific risk factors
also contribute to this increased cardiovascular risk in
ESKD patients. This relates, in part, to abnormal diva-
lent ion mineral metabolism that occurs in the renalpopulation [2]. In particular, these patients demonstrate
extensive cardiovascular calcification, including that of
coronary arteries and cardiac valves, that progresses more
rapidly as their kidney disease deteriorates and has been
associated with an increased cardiovascular mortality
[3-7]. Matrix Gla protein (MGP) and osteocalcin (OC) are
two proteins that regulate mineralization of vascular tis-
sues and bone, respectively [8,9]. In addition to its critical
role in coagulation, vitamin K is a cofactor for post-
translational modification that is critical for these proteins
to exert their protective biological effects, with evidence of
increased mortality among ESKD patients with low levels
of carboxylated MGP [10]. The function of these vitamin
K dependent proteins (VKDP) is sensitive to vitamin K
status, and therefore vitamin K could represent a modifi-
able target in the management of cardiovascular disease in
this patient population.
Phylloquinone (vitamin K1) is the primary North
American dietary source and circulating form of vitamin
K [11]. In the presence of severe dietary restriction of
phylloquinone, there is an increase in the undercarboxy-
lated forms of the VKDPs [12,13]. Osteocalcin (OC) is a
noncollagenous bone matrix protein synthesized by
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boxylated (%ucOC) has been used extensively in the
non-renal population as a sensitive marker of vitamin K
status in bone. Subclinical vitamin K deficiency is defined
by an increase in %ucOC above 20% and predisposes to re-
duced bone mineral density and fractures [14-18]. Protein
induced by the vitamin K absence or antagonism factor-II
(PIVKA-II) is a measure of prothrombin undercarboxyla-
tion, with elevated levels corresponding to poorer vitamin
K status. In the ESKD population, PIVKA-II measurements
have the advantage of not being affected by renal function
[19] but until recently had only been measured in dialysis
patients with hepatitis C.
Westenfeld et al recently evaluated the impact of 3
doses of vitamin K2 on levels of ucMGP, PIVKA-II, %
ucOC and vitamin K2 in 53 prevalent hemodialysis pa-
tients [20]. They demonstrated a dose-dependent de-
crease in levels of ucMGP and PIVKA-II, while levels of
%ucOC were only changed at the highest dose of vita-
min K2. While %ucOC is a useful measure of functional
vitamin K status in the general population, the spectrum
of mineral and bone disorders and potential for accumu-
lation of OC in those with renal failure may render it a
less useful measure in dialysis patients.
These studies indicate that many hemodialysis patients
have functional, but modifiable, vitamin K deficiency.
Examining the correlates of poor vitamin K status in dia-
lysis patients might therefore aid in identifying those
individuals at risk. At present, no single biomarker is a
robust measure of vitamin K sufficiency and deficiency.
Therefore, multiple biomarkers are used where possible,
each of which reflects a different aspect of vitamin K
intake, absorption, transport or function as a co-factor
for the gamma-carboxylation of VKDPs. Therefore, the
purpose of this study was determine the correlates of
three estimates of vitamin K status (phylloquinone levels,
PIVKA-II and %ucOC) in a prevalent cohort of Canadian
hemodialysis patients and to assess the association be-
tween these circulating measures of vitamin K status in in-
dividuals with end-stage kidney disease.
Methods
Study population
This cross-sectional study included 44 patients receiving
hemodialysis (HD) for irreversible chronic kidney disease
(CKD) at Kingston General Hospital, Ontario, Canada or
one of its satellite dialysis centers. Consecutive patients
greater than 18 years of age were approached during one
of their scheduled outpatient hemodialysis sessions. All
patients provided informed consent according the Declar-
ation of Helsinki. Procedures were in accordance with the
ethical standards of Queen’s University and approved by
the Tufts Medical Center Institutional Review Board
(Boston, MA). Of 123 patients considered for this study,44 consented for enrollment and none subsequently with-
drew. Subjects were excluded from the study protocol if
they were unwilling (n = 21) or unable (n = 10) to provide
consent; if they had been exposed to warfarin (a vitamin K
antagonist) within the preceding year (n = 44); or if they
were hospitalized at the time of enrollment (n = 4).
Analytical measures
Clinical data were abstracted by patient interview and
review of hemodialysis charts for the following parame-
ters: age, sex, smoking status, history of coronary artery
disease (CAD), history of cerebrovascular disease (CVD),
presence of peripheral vascular disease (PVD), history of
diabetes mellitus (DM), history of fractures, etiology of
renal failure, dialysis vintage, and adequacy of hemodialysis
as measured by the most recently recorded single pool Kt/
V calculated from the urea reduction ratio (URR). The
presence of coronary artery disease was determined both
by current symptoms (patient interview) using Canadian
Cardiovascular Society functional classification of angina
and history of cardiovascular events including acute coron-
ary syndrome [21]. CVD included a history of cerebral
vascular accident or transient ischemic attack. PVD was
determined by the presence of claudication or peripheral
revascularization surgery. Patients were considered current
smokers if they had smoked at least one cigarette per day
during the preceding six months, former smokers if they
had abstained from smoking for at least one month after
having smoked at least one cigarette per day for six
months, and non-smokers if they had never smoked.
Laboratory measures
Laboratory measures included ionized calcium (mmol/
L) and phosphate (mmol/L) that were averaged over the
three previous months, intact parathyroid hormone
(PTH) (pmol/L), serum albumin (g/L), total cholesterol
(mmol/L), LDL cholesterol (mmol/L), HDL cholesterol
(mmol/L), and triglycerides (mmol/L). Intact PTH was
assessed by means of electrochemiluminescence (Roche,
Basel, Switzerland) modular analytics E170 immuno-
assay. Serum albumin was measured by the bromocresol
green method (Roche, Basel, Switzerland). All of the
aforementioned analyses were performed in the labora-
tory at Kingston General Hospital to minimize interla-
boratory variability. Blood samples were stored at -80°C
before the analysis of phylloquinone,%ucOC, and PIVKA-
II. Fasting phylloquinone concentrations were measured
using reversed-phase high-performance liquid chromatog-
raphy [22,23]. Osteocalcin (OC) was measured in serum
by a radioimmunoassay that uses human OC for standard
and tracer and a polyclonal antibody that recognizes intact
OC and the large N-terminal midmolecule fragment.
Uncarboxylated OC (ucOC) was determined in this assay
as OC that does not bind in vitro to hydroxyapatite [23].
Table 1 Demographic and clinical features of study
population
Variables N (%) Mean ± SD Range
Clinical characteristics (n = 44)
Age, years 64.2 ± 14.5 22 to 92
Sex (male) 29 (65.9)
Dialysis vintage, months 43.8 ± 38.3 3 to 183
Etiology of ESKD
Diabetes mellitus 11 (25.0)
Renovascular disease 14 (31.8)
Other 19 (43.2)
Cardiovascular disease 14 (31.8)
Peripheral vascular disease 17 (38.6)
Cerebrovascular disease 6 (13.6)




nmol/L (n = 44)
1.25 ± 1.17 0 to 5.3
%ucOC (n = 42) 24.5 ± 15.4 5.2 to 63.1
PIVKA-II, nmol/L (n = 44) 3.98 ± 2.51 1.5 to 14.5
Laboratory measures
Phosphate, mmol/L (n = 43) 1.49 ± 0.38 0.61 to 2.96
Calcium, ionized, mmol/L
(n = 43)
1.17 ± 0.08 0.97 to 1.36
Parathyroid hormone, pmol/L
(n = 43)
38.7 ± 39.4 0.9 to 220.1
Albumin, g/L (n = 43) 40.4 ± 3.2 32 to 48
Total cholesterol, mmol/L
(n = 43)
3.74 ± 0.86 2.1 to 6.3
LDL cholesterol, mmol/L (n = 41) 1.62 ± 0.63 0.4 to 3.1
HDL cholesterol, mmol/L (n = 43) 1.30 ± 0.35 0.7 to 2.3
Triglycerides, mmol/L (n = 43) 1.75 ± 1.23 0.8 to 5.6
Kt/V (n = 44) 1.52 ± 0.35 0.71 to 2.23
URR (n = 44) 0.73 ± 0.07 0.50 to 0.88
ESKD, End-stage kidney disease; %ucOC, percentage of undercarboxylated
osteocalcin; PIVKA-II, Proteins induced by vitamin K absence or antagonism II;
LDL, low-density lipoprotein; HDL, high-density lipoprotein; Kt/V, measure of
dialysis adequacy, where K is dialyzer clearance of urea, t is dialysis time, and V
is volume of distribution of urea; URR, urea reduction ratio.
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that is not carboxylated (%ucOC), and a value >20% is
consistent with subclinical vitamin K deficiency. This cut-
off point is specific to this assay and should not be consid-
ered generalizable to other assays used for determination
of %ucOC. PIVKA-II concentrations were determined by
ELISA (Diagnostica Stago, Parsippany, NJ).
Statistical analysis
All data were analyzed using the PASW software package
(version 18.0, Chicago, IL). Descriptive statistics (mean ±
SD for continuous data and frequency for categorical
values) were generated for all variables. Spearman correl-
ation coefficient was used to evaluate bivariate relationships
among biomarkers of vitamin K status and continuous
variables. To evaluate the relationship between vitamin K
biomarkers and categorical variables, non-parametric tests
including Mann Whitney U and Kruskal-Wallis H were ap-
plied as appropriate for two-level or multiple comparisons,
respectively. Multivariable linear regression models were
applied to determine independent predictors of vitamin K
status using the backward-selection method. All statistical
tests were two-sided, and an unadjusted P value of 0.05 or
less was considered statistically significant.
Results
Baseline demographic data for the study population are
listed in Table 1. There were 44 HD patients with a mean
age of 64.2 years (range 22 to 92 years) and mean dialysis
duration of 43.8 ± 38.3 months (range 3 to 183 months)
enrolled in this study.
The mean serum PIVKA-II level measured in 44 patients
was 3.98 ± 2.51 nmol/L. Of these, 90.9% had subclinical
vitamin K deficiency defined as PIVKA-II levels > 2 nmol/
L. Higher PIVKA-II levels, corresponding to worse vitamin
K status, were associated with increasing age, decreasing
HDL and lower Kt/V, or inadequate dialysis (Table 2).
There was no association between PIVKA-II levels and
other lipid measures. Those with CAD had higher PIVKA-
II levels on average (mean 5.16 ± 3.26 nmol/L) compared
to those without CAD (mean 3.44 ± 1.90 nmol/L) (P =
0.009). There was a trend towards positive association with
PVD and smoking status. The only independent predictor
of PIVKA-II concentration was advancing age; for every
10-year increase in age, serum PIVKA-II levels increased
by 0.5 nmol/L (Table 3). Those with CAD trended toward
higher mean PIVKA-II levels in the multi-variable model,
but this was not statistically significant.
Overall mean serum phylloquinone concentration in
44 patients was 1.25 ± 1.17 nmol/L (normal range 0.4 to
2.4 nmol/L [24]). Six patients (13.6%) met criteria for
subclinical vitamin K deficiency, with phylloquinone levels
below the normal range. Higher phylloquinone concentra-
tions were positively associated with serum triglyceridelevels and total cholesterol levels but not with LDL or
HDL levels (Table 2). Current smokers had lower levels of
serum phylloquinone than former smokers or lifelong non-
smokers. The single independent predictor of phyllo-
quinone concentration by regression analysis was serum
triglycerides; on average, for every 1.0 mmol/L increase in
triglycerides, serum phylloquinone increases by 0.53 nmol/
L (P = 0.001) (Table 3). There was no association between
serum phylloquinone and age, CAD, or calcium and phos-
phate laboratory parameters.
Table 2 Cross-sectional correlations among measures of vitamin K status, demographic and biochemical variables
Variables Phylloquinone %ucOC PIVKA-II
r p r p r p
Demographic variables
Age, years 0.108 0.49 0.063 0.69 0.37 0.015
Dialysis vintage, months -0.25 0.11 0.06 0.72 -0.04 0.82
Mean ± SD p Mean ± SD p Mean ± SD p
Sex






Female 1.21 ± 1.08 22.9 ± 13.4 4.09 ± 2.66
Etiology of ESKD





0.22Renovascular disease 1.33 ± 1.34 25.5 ± 15.0 4.48 ± 3.10
Other 1.25 ± 1.19 24.3 ± 15.7 3.55 ± 2.35






No 1.29 ± 1.25 26.9 ± 15.9 3.44 ± 1.90






No 1.24 ± 1.06 25.4 ± 15.9 3.59 ± 2.33






No 1.26 ± 1.19 26.0 ± 15.3 3.79 ± 2.22






No 1.44 ± 1.31 27.9 ± 15.1 3.93 ± 2.31





0.09Former 1.65 ± 1.47 24.2 ± 13.4 4.44 ± 2.51
Never 1.12 ± 0.84 22.4 ± 15.4 3.59 ± 2.98
r p r p r p
Laboratory variables
Phosphate, mmol/L -0.05 0.77 0.30 0.06 0.15 0.35
Calcium, ionized, mmol/L 0.15 0.33 0.22 0.18 0.08 0.63
Calcium-phosphate product, mmol2/L2 0.06 0.69 0.40 0.009 0.20 0.19
PTH, pmol/L 0.05 0.76 -0.26 0.10 -0.05 0.74
Albumin, g/L -0.003 0.99 -0.07 0.66 -0.07 0.65
Total cholesterol, mmol/L 0.43 0.004 0.14 0.39 0.14 0.37
LDL cholesterol, mmol/L 0.17 0.30 0.22 0.18 0.21 0.19
HDL cholesterol, mmol/L -0.04 0.82 0.26 0.10 -0.31 0.046
Triglycerides, mmol/L 0.45 0.002 -0.13 0.42 0.19 0.22
Kt/V 0.11 0.48 0.15 0.35 -0.33 0.027
URR 0.04 0.80 0.05 0.73 -0.06 0.68
ESKD, End-stage kidney disease; PTH, Parathyroid hormone; LDL, Low-density lipoprotein; HDL, High-density lipoprotein; Kt/V, measure of dialysis adequacy; URR,
urea reduction ratio.
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ical vitamin K deficiency criteria defined as >20% ucOC
was met in 21 patients (51%). Higher %ucOC (and,
therefore, poorer vitamin K status) was associated with a
higher calcium-phosphate product (Table 2). Prior cere-
brovascular events and a history of fractures were nega-
tively associated with %ucOC. Higher levels of %ucOCwere independently associated with increasing serum
phosphate and lower serum PTH levels (Table 3). There
was no association between %ucOC and age, sex, dialysis
adequacy, or smoking status.
There was no association between any one biomarker
of vitamin K status with the other measures of vitamin
K status (Table 4). There were no significant associations
Table 3 Multivariable linear regression models for
significant predictors of phylloquinone, %ucOC and
PIVKA-II
β Coefficient 95% Confidence
interval
p
Phylloquinone (R2 = 0.275,
n = 42)
Triglycerides 0.54 0.25 to 0.84 0.001
Total cholesterol -0.036 -0.46 to 0.39 0.87
%ucOC (R2 = 0.14, n = 41)
Phosphate 14.80 1.71 to 29.13 0.028
PTH -0.14 -0.26 to -0.02 0.028
Coronary artery disease -9.14 -18.73 to 0.46 0.061
PIVKA-II (R2 = 0.16, n = 43)
Age, years 0.05 0.01 to 0.10 0.033
Coronary artery disease 1.40 -0.14 to 2.93 0.07
PTH, parathyroid hormone; %ucOC, percentage of uncarboyxlated osteocalcin;
PIVKA-II, proteins induced by vitamin K absence or antagonism.
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sex, etiology of ESKD, dialysis vintage, or serum albumin
(Table 2).
Discussion
The present study confirms previous reports that a sub-
optimal vitamin K status is prevalent in patients with
ESKD [10,17,25-27]. Based on ranges determined in
healthy adults, over 90% of these HD patients had in-
creased PIVKA-II levels, confirming that a high preva-
lence of subclinical vitamin K deficiency exists in this
population, particularly in older patients. Although clinical
outcome studies are lacking, PIVKA-II may be a good bio-
marker of vitamin K status in this particular population as
its measurement is not influenced by kidney function [19],
and it has been demonstrated to respond in a dose- and
time-dependent manner to vitamin K2 supplementation
in hemodialysis patients [20]. We found no associations
between phylloquinone levels and the two estimates of
functional vitamin K status in this study, which may re-
flect dysregulation in metabolism that is associated with
uremia and directly impacts vitamin K biomarkers.
The results of this small study support those of a
recent trial examining the effect of oral vitamin K2Table 4 Cross-sectional associations between biomarkers
of vitamin K status
Variables Phylloquinone %ucOC PIVKA-II
r p r p r p
Phylloquinone 0.09 0.58 -0.18 0.25
%ucOC 0.09 0.58 0.08 0.62
PIVKA-II -0.18 0.25 0.08 0.62
%ucOC, percentage undercarboxylated osteocalcin; PIVKA-II, Protein induced
by vitamin K absence or antagonism II.supplementation on biomarkers of functional vitamin K
status in a cohort of 53 hemodialysis patients [20]. In
this trial, the mean PIVKA-II level at baseline prior to
supplementation was 5.6 ng/mL (reference < 2 ng/mL),
with 49 of 50 patients having levels above the cited refer-
ence range. Similarly, baseline levels of uncarboxylated
osteocalcin and dephosphorylated-uncarboxylated MGP
were 8.4-fold and 4.5-fold higher than population-matched
controls, respectively. There was a significant dose- and
time-dependent improvement in functional vitamin K indi-
ces over the 6-week supplementation period, with subse-
quent rebound in dephosphorylated-uncarboxylated MGP
levels following cessation of therapy [20]. This study sug-
gests hemodialysis patients respond to vitamin K2 supple-
mentation in terms of favorable biomarker responses.
However, trials and large longitudinal studies linking vita-
min K supplementation to clinical outcomes are currently
needed to clarify the role of the various biomarkers of vita-
min K deficiency. Functional vitamin K deficiency as mea-
sured by levels of dephosphorylated-uncarboxylated MGP
(dp-ucMGP) has been associated with increased all-cause
and cardiovascular mortality risk in dialysis patients [10].
However, the dp-ucMGP fraction is responsive to vitamin
K supplementation. The physiology and biochemistry of
MGP will only be clarified by longitudinal analysis of vita-
min K biomarkers in population studies.
In our study, the mean PIVKA-II concentration was
3.98 ± 2.51 nmol/L and, similar to the Westenfeld study
[20], the overwhelming majority of patients (91%) met
criteria for sub-clinical vitamin K deficiency. In our study,
higher concentrations of PIVKA-II were associated with
advancing age, the presence of cardiovascular and periph-
eral vascular disease and poorer dialysis adequacy; however
in the multivariable model only age remained significant.
By way of comparison, PIVKA-II levels were measured
using identical techniques and in the same laboratory as
this study in two previous reports. In a cohort of 416
community-dwelling elderly subjects, the mean (SD) of
PIVKA-II at baseline was lower at 2.43 (0.06) nmol/L [28].
A second study assessed PIVKA-II concentrations in
younger patients with rheumatoid arthritis prior to supple-
mentation with vitamin E. The mean (SD) of PIVKA-II at
baseline in this younger group was 1.7 (1.7) nmol/L [29].
Phylloquinone concentrations are believed to reflect tis-
sue levels and are influenced by dietary intake. Based on
ranges determined in healthy adults, we previously dem-
onstrated in a larger cohort of HD patients that 29% had
very low (<0.4 nM/L) circulating concentrations of phyllo-
quinone [25]. In this smaller cohort, only 13.6% had very
low levels, and the reasons for this difference are unknown
but may reflect differences in vitamin K intake between
the two cohorts, which were not captured. Similar to our
previous study, there was a strong independent relation-
ship between phylloquinone and triglyceride levels. Studies
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primarily by triacylglycerol-rich lipoproteins (including
chylomicron remnants and very low density lipoproteins)
following absorption, while little is carried by low-density
or high-density lipoprotein fractions [30]. ESKD is associ-
ated with defects in reverse cholesterol transport and is
typically characterized by elevated triglycerides and low
HDL-cholesterol. Therefore, interpretation of circulating
phylloquinone level as a biomarker of vitamin K status dir-
ectly related to dietary intake in patients with ESKD is un-
certain. However, in a cross-sectional study of prevalent
HD patients, lower circulating levels of phylloquinone
were the strongest predictor for the presence of a vertebral
fracture, suggesting that phylloquinone level is relevant to
bone health in this population [31].
Sixty percent of subjects had elevated concentrations
of %ucOC and therefore met the criteria for sub-clinical
vitamin K deficiency as it is defined in the general popula-
tion. This is significantly greater than the mean %ucOC in
the Framingham Offspring Study population (16.1% in
males and 23.5% in post-menopausal women), in which
the assessment of %ucOC was performed in the same la-
boratory. Total OC levels are significantly increased in pa-
tients with ESKD due to a combination of bone resorption
and retention, but it is unknown if the γ-carboxylated frac-
tion in circulation reflects vitamin K status in bone. Similar
to our previous studies, we found strong association be-
tween %ucOC and parameters of mineral metabolism (i.e.
elevated calcium-phosphorus product).
We found no associations between phylloquinone levels
and the two estimates of functional vitamin K status in
this study. In addition, our group and others have not
demonstrated an association between phylloquinone and
%ucOC in larger cohorts of patients with CKD [17,25-27].
In contrast, longitudinal studies of vitamin K status per-
formed in the general community-dwelling population
generally report significant negative correlations between
phylloquinone levels and both functional estimates of vita-
min K status in liver (PIVKA-II) and bone (%ucOC). This
discrepancy may reflect the cross-sectional nature of this
small study, or alternatively it may highlight the limita-
tions of using these biomarkers of vitamin K status in pa-
tients with ESKD in whom metabolic dysregulation can
directly impact their estimates. In addition, the correlates
of poor vitamin K status were different depending on the
biomarker considered.
Vitamin K deficiency in the ESKD population likely re-
lates, in part, to overall low caloric intake or dietary pat-
terns that preclude the intake of vitamin K-rich foods. This
was confirmed in a recent study of 40 hemodialysis patients
that involved a 4-day food record [32]. The vitamin K1 was
low in these patients (median 140 ug/day) compared to in-
takes reported in a reference population of healthy adults
(median 200 ug/day). Although the daily Adequate Intake(AI) of vitamin K for adult men and women is 90 and 120
ug, respectively [33], this is the amount considered suffi-
cient to prevent frank vitamin K deficiency and coagulopa-
thy but may be inadequate for complete extra-hepatic
VKDP carboxylation [12,34]. In the ESKD population, a
state of subclinical vitamin K deficiency resulting from pro-
longed nutritional deficiency may further accelerate their
risk of VC and cardiovascular morbidity.
The small sample size and broad range in dialysis vin-
tage observed in this cohort limit the conclusions that
may be drawn. However, the results of this study support
previous work that indicates there is a very high preva-
lence of subclinical vitamin K deficiency in the ESKD
population. These patients therefore may be at risk for
any biological consequences of vitamin K deficiency.
There is an emerging role for vitamin K in oxidative
stress reduction and a growing body of literature links
poor vitamin K status with arterial calcification [35,36].
One recent report in dialysis patients has linked the
presence of dephosphorylated-uncarboxylated MGP in
the circulation to calcification outcomes in patients with
ESKD; however, no other biomarker of vitamin K status
was simultaneously assessed in this study [36].
Conclusions
In this study, we found that a significant proportion of HD
patients met criteria for subclinical vitamin K deficiency. Of
the biomarkers measured, PIVKA-II may be superior given
its independence of renal function or dyslipidemia, both of
which may confound the other vitamin K biomarkers.
Studies in patients with ESKD linking biomarkers of vita-
min K status to important patient outcomes, including car-
diovascular disease, nutritional status and mortality, are
required in order to determine the optimal biomarker for
evaluating vitamin K status in this particular population.
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